Tirbanibulin
Tirbanibulin
Five days, then you stop. The shortest course in this register and the largest treatment difference after bimatoprost — for the photodamaged population every anti-ageing trial excluded.
The marker is the strength the trials were actually run at. The bar is the span this register has recorded, approved and compounded together. Anything below the marker is a dose nobody has tested; anything above it is an assumption about a dose–response curve nobody has drawn.
The shaded band is the depth this molecule is understood to reach. Anything below it is out of scope, whatever the label says.
Mechanism
Disrupts tubulin polymerisation in rapidly proliferating cells. Applied as a field treatment rather than lesion by lesion, so it acts on the subclinical damage around visible lesions as well as the lesions themselves.
HOUSE NOTES
- Unit-dose packets remove the dosing judgement entirely — one packet, once a day, five days, with nothing left to over-apply.
- The endpoint was complete clearance: no clinically visible lesions remaining, not fewer.
- Local skin reactions are severe by the standards of this register — erythema worse than baseline in 91% of subjects — and they are the treatment working over a five-day course that then heals.
- The face clears roughly twice as reliably as the scalp, and the label reports the two separately rather than pooling them.
- Its trial population averaged 70 years old. Renova's excluded anyone with visible actinic keratosis, which is the same population seen from the other side.
MEASURED ENDPOINTS
SUPPORTING RECORDS
Double-blind, vehicle-controlled, five-day course; average subject age 70, range 45 to 96
N=351 · 8 WK · DOUBLE-BLIND
Investigator-graded local skin reactions in the treatment area, pooled across both Phase 3 trials
N=702 · 8 WK · DOUBLE-BLIND
Layering
- Occlusion after application
- Skin not yet healed from prior treatment or surgery
- Eyes, mouth and nostrils
- Daily sunscreen, permanently, afterwards